Winterthur, ZH - January 21, 2026 - PRESSADVANTAGE - daylight AG, a Winterthur-based educational technology company, ...

We expect investors to focus on the sales performance of Amicus Therapeutics’ FOLD marketed products and updates related to its recently announced merger agreement with BioMarin Pharmaceutical BMRN ...

At WSJ Invest Live, Jon Gray shared optimism for the health of the private-credit market and discussed Blackstone’s investment strategy in AI infrastructure. Investors’ fears that new developments in ...

Monday - Friday, 6:00 - 7:00 PM ET There's a key metric that highlights why software stocks like ServiceNow are underperforming, according to Jim Cramer. He pointed to the decline in price-to-earnings ...

A lot of people requested this one for their HyperX Alloy Origins Core because they are concerned that the keyboard can't save rgb profiles or Macros, but it can. Just remember to sync to your ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease candidate it had once hoped would become a best-in-class treatment. The oral ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...

BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases. The ‍drugmaker will ‍pay $14.50 per share for ...

The all-cash acquisition price translates to $14.50 per share, valuing the offer at a 33% premium to Amicus's last close, a 46% premium to its 30-day average price, and a 58% premium to its 60-day ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...